News

Open access drug development tools feature in new IMI Call for proposals

Open access drug development tools feature in new IMI Call for proposals

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of the Call is over EUR 80 million. Half of this comes from the European Commission’s Horizon 2020 programme and will fund the participation in the projects of universities, small and medium-sized companies, patient groups etc. The other half comes from large pharmaceutical companies and IMI Associated Partners, who do not receive EU funding through IMI but finance their own participation in our projects.

Open access tools for the genetics of disease – Many diseases have a genetic component, yet we lack the tools to study many of the genes behind diseases. This topic aims to develop a set of open access tools to facilitate the study around 1 000 of the 3 000 genes thought to be implicated in disease and that could be targeted by drugs. The results of the project will be made fully available to the scientific community by open access.  

Optimising future obesity treatment – Obesity affects some 650 million people globally, placing them at greater risk of complications such as heart disease, diabetes and cancer to name a few. This topic aims to better understand obesity as a disease by identifying subgroups of people with obesity that will ultimately pave the way for better, more personalised prevention and lifestyle interventions, as well as treatments for obesity and its complications. The project will also focus on diabetes (both types 1 and 2) as examples of conditions that are influenced by obesity in a complex way.

Environmental impacts of medicines – Active ingredients from medicines can get into the environment through a variety of routes, and once there they can prove harmful to wildlife and ecosystems. In the EU, new medicines are required to undergo an environmental risk assessment (ERA). This topic will help to reduce the impact of medicines on the environment in three ways. Firstly, it will deliver tools to identify environmental risks associated with medicines under development. Secondly, it will prioritise which existing medicines (introduced before the ERA) should go through a tailored environmental assessment. Finally, it will create a publicly-available database to make environmental data on human medicinal products more transparent to all stakeholders.

Pierre Meulien, IMI Executive Director commented: ‘If we want to enjoy the benefits of the genomic revolution, we have to develop tools to study in detail the genes that influence our health. By taking an open access approach, the new topic launched as part of today’s Call for proposals will maximise the impacts of its results by making it possible for researchers worldwide to access and use them in their own work.

Info related to the calls is here

Webinars on all three funds here 

More info here 

NEWS​

Related News

Dive into the Future of Healthcare with the Essentials of Digital Health Certificate Course!

18 Jul 2024
“You are going to hit a zone of professional irrelevance if you do not know Digital Health.”  ~ Dr. Rajendra Pratap Gupta, Chairman, Academy of Digita...

The report for the 2nd Africa Women’s Health Symposium is now available!

17 Jul 2024
For over half a decade, Africa Health Business has convened stakeholders from across the African health sector to address and find solutions to critic...

Join the Africa Digital Health Revolution with ADHN

17 Jul 2024
The Africa Digital Health Network (ADHN) invites all stakeholders in health and technology to join us in revolutionizing healthcare across the contine...

Have your say: Open Public Consultation for the BeWell Skills Strategy

17 Jul 2024

Fit 4 Start #15 open to healthtech, digital, and space startups

16 Jul 2024
For its 15th edition, Luxembourg’s startup accelerator Fit 4 Start is accepting applications from innovative healthtech, digital, and space enterprise...

Rivne Interregional Medical Cluster became a member of the project consortium PRECISEU

16 Jul 2024
Ukraine, represented by the Rivne Interregional Medical Cluster, became a member of the project consortium PRECISEU

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *